Scipher Medicine Announces Publication of Positive AIMS Clinical Study Results

Scipher Medicine Announces Publication of Positive AIMS Clinical Study Results

Patients were 3.1 times more likely to achieve their treatment goals when tested with PrismRA®

Demonstrates significantly superior results compared to standard of care in analysis of 3,348 patients

WALTHAM, Mass., November 11, 2022–(BUSINESS WIRE)–Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test to guide treatment selection for patients with rheumatoid arthritis (RA). The latest publication in the Expert review of molecular diagnostics showed that patients whose care included the PrismRA test had significantly better clinical outcomes compared to the current standard of care (SOC).

Scipher Medicine, a precision immunology company that matches every patient with their most effective treatment, has developed its proprietary PrismRA blood test, which predicts non-response to the world’s largest class of drugs, necrosis factor inhibitors (TNFi) in patients with RA. TNFs are commonly used to treat rheumatoid arthritis, but many patients fail to achieve an optimal response. As a result, many patients endure a trial-and-error-and-failure-first treatment odyssey, resulting in poorly controlled disease, irreversible joint damage, and an increased risk of cardiovascular disease, cancer, and death. PrismRA guides treatment choice and helps RA patients find their most effective treatment sooner.

Study data revealed that RA patients with moderate to high disease activity whose treatment was guided by PrismRA were up to three times more likely to achieve treatment goals compared to SOC . Treatment goals were defined as low disease activity or remission six months after the start of treatment. The AIMS study included more than 70 private and academic rheumatology practices across the United States, 627 patients tested with PrismRA, and a control group of 2,721 patients, derived and matched from a database of health records electronics.

Building on Scipher’s previous clinical research, these results represent the first comparison between PrismRA and SOC treatment selection practices, adding further evidence in support of the clinical utility of PrismRA to improve outcomes and inform the selection of treatment for patients with RA.

“Current standard-of-care practices generally fail to meet treatment goals to target low disease activity or remission, in part due to the challenge of selecting the most beneficial therapy for patients,” said the Study co-author Jeffrey Curtis, MD, MS, MPH, professor of medicine, epidemiology, and computer science in the Division of Immunology and Rheumatology at the University of Alabama at Birmingham. “Data from this study showed significant improvement in clinical outcomes. This, in turn, may lead to decreased frequent and costly medication changes, decreased risk of drug toxicity from therapies that are ultimately ineffective for specific patients and prevention of irreversible joint damage for patients with RA.”

“The ineffective use of trial and error methods when prescribing RA treatment has become far too common, leading to suboptimal clinical responses and, ultimately, increased drug costs. health,” said Sam Asgarian, MD, chief medical officer at Scipher Medicine. “Building on the work of our two previous studies, these results provide further evidence that large-scale adoption of PrismRA could change the treatment landscape for patients with RA by bringing personalized medicine to the forefront of care. “

About Cipher Medicine®

Scipher Medicine, a precision immunology company that matches every patient with their most effective therapy, believes that patients deserve simple answers to science-based treatment options. Using Spectra™, our proprietary networked medicine platform, we bring to market tests that reveal the unique molecular signature of a person’s disease and match it to the most effective therapy, ensuring optimal treatment from first day. The molecular data generated from our assays further supports the discovery and development of new and more effective therapies. We partner with major payers, healthcare providers and pharmaceutical companies to bring precision medicine solutions to patients with autoimmune diseases. Visit and follow Scipher Medicine on Twitter, Facebook and LinkedIn.

See the source version on


Media Relations
Business communication

Investor Relations

#Scipher #Medicine #Announces #Publication #Positive #AIMS #Clinical #Study #Results

Leave a Comment

Your email address will not be published. Required fields are marked *